Protocol Ledger

NCT07454915 · Phase II · RECRUITING

PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia

Interventional Phase II clinical trial protocol NCT07454915 sponsored by PapiVax Biotech in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-01 Enrollment: 138 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07454915
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)138 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07454915
Protocol FieldVerified Registry Value
NCT IdentifierNCT07454915
Consolidated Lead SponsorPapiVax Biotech
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment138 participants (ESTIMATED)
Registered Start Date2026-04-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07454915
Hospital Research SiteLocationSite Profile
Montefiore Medical CenterThe Bronx, NYOpen Hospital Dossier ->
China Medical University HospitalTaichung, TaiwanOpen Hospital Dossier ->
Taichung Veterans General HospitalTaichung, TaiwanOpen Hospital Dossier ->
National Cheng Kung University HospitalTainan, TaiwanOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI